Jubilant Pharmova Limited
Valuation (85/100) does the heavy lifting; momentum (27/100) is the drag.
Buy zoneSolvency riskJubilant Pharmova Limited earns a Sell from StocksWizard, with a blended score of 40/100. At ₹935.15 it trades below our blended DCF and relative-multiples fair value of ₹1,543.87, about 65% upside to that estimate — we read it as undervalued by 65%. On 38.5x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 21% below its 52-week high of ₹1,187.95 and 16% above the low of ₹803.49. Financial health scores 31/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹1,139 implies about 22% upside across 2 analysts. It clears 4 of 13 investability checks, with durability 33, valuation 70 and momentum 27 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,235.09.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-21.28% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell40Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 6.0%
- Fail: Low debt (D/E < 0.5): 0.51x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 19%
- Fail: Earnings growing: -22%
- Fail: Net margin ≥ 10%: 4.8%
- Pass: Current ratio > 1.5: 1.62
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.22
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter57.9%
- Institutions21.8%
- Public & other20.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Revenue growing (19% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~65% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (6.0%).
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (3/9).
Threats
- Earnings contracting year on year.
About Jubilant Pharmova Limited
Jubilant Pharmova Limited is an integrated pharmaceutical company operating across India, the Americas, Europe, and internationally through six business segments: Radiopharma, which produces radiopharmaceuticals for diagnostic and treatment applications; Allergy Immunotherapy; Contract Development and Manufacturing Organisation for Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs.
Jubilant Pharmova Limited — frequently asked questions
Is Jubilant Pharmova Limited a buy, hold or sell?
StocksWizard currently rates Jubilant Pharmova Limited (JUBLPHARMA) a Sell, based on a blended score of 40/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Jubilant Pharmova Limited's fair value?
Our blended DCF and relative-valuation model estimates Jubilant Pharmova Limited's fair value at about ₹1,543.87, versus a current price of ₹935.15 — roughly 65% upside. On that basis the stock looks undervalued by 65%.
Is Jubilant Pharmova Limited financially healthy?
Jubilant Pharmova Limited scores 31/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Jubilant Pharmova Limited's share price performed?
Jubilant Pharmova Limited is roughly flat over three months, and last traded at ₹935.15. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.